CREATIVE APPROACHES TO IMPROVING ACCESS TO MEDICINES GLOBALLY

Dr Bernard Pécoul, DNDi Executive Director
3 December 2019, 10:00 - 17:00
Auditorium Ivan Pictet, Maison de la Paix, Geneva
Abundant R&D pipeline for HCV in 2015... but many drug candidates abandoned
DNDi Hepatitis C Strategy: 3 pillars

1. Accelerate R&D
   - Accelerating the development of ravidasvir
   - with Pharma companies, Governments

2. Catalyse ACCESS
   - Supporting affordable access to all DAAs
   - with Pharma companies, Civil Society organisations, Governments

3. Simplify TREATMENT STRATEGIES
   - Working with health providers to scale-up treatment
   - with Primary healthcare doctors, Non Governmental Organizations
Public Interest R&D partnerships: affordable treatments
Voluntary Licences exclude more than 25 percent of HCV infected people in MICs
DAAs prices depend on IP status and Government leadership
(prices in US$ per 12 weeks)
Only 5 million people treated in 2013-2017 worldwide

1.8M people treated
2.5M people treated
0.7M people treated

66M people remain to be treated by 2030
Simplification of HCV model of care will be critical to detect and treat 80% of patients still unaware of their status.

THANK YOU FOR YOUR ATTENTION